Endo to Combine With Mallinckrodt in $6.7 Billion Deal

Paul, Weiss is advising pharmaceutical company Endo, Inc., in its cash-and-stock combination with Mallinckrodt plc, creating a global, scaled and diversified pharmaceuticals leader with an implied enterprise value of $6.7 billion. Under the terms of the transaction, Endo shareholders will receive a total of $80 million in cash and will own 49.9% of the combined company, with Mallinckrodt shareholders owning the remainder.

Endo and Mallinckrodt plan to combine their generic pharmaceuticals businesses and Endo’s sterile injectables business and separate that business from the combined company at a later date. Upon closing, expected in the second half of 2025, subject to shareholder and regulatory approvals and customary closing conditions, Endo will become a wholly owned subsidiary of Mallinckrodt.

The Paul, Weiss team is led by corporate partners Jim Langston and Chelsea Darnell, and includes partners John Kennedy, Carmen Lu and Patricia Vaz de Almeida; tax partner Brian Krause; and litigation partners Geoffrey Chepiga and Andre Bouchard.